Final results of STRATEGYA Study (Russian Comparative Programme on a fixed, low-dose perindopril/indapamide combination efficacy in hypertensive patients with inadequate blood pressure control): use of a fixed, low- dose perindopril/indapamide combination in hypertensive patients in real clinical practice
Abstract
which Noliprel and if necessary Noliprel forte may be recommended.
Results. In 4 wks of treatment SBP mean values were significantly reduced from 158±19 mm Hg to 131±11mm Hg (p<0,05),
DBP - from 94±8 mm Hg to 81±6 mm Hg (p<0,05). According to BP-monitoring in 16 wks of treatment SBP mean values were significantly
reduced from 155±25 mm Hg to 127,5±9,9 mm Hg (p<0,05) in the 1st subgroup; from 157±14 mm Hg to 131,1±11 mm
Hg (p<0,05) in the 2d subgroup; from 163±14 mm Hg to 133,7±12 mm Hg (p<0,05) in the 3d subgroup accordingly; DBP mean
values were decreased from 93±8 mm Hg to 79,8±5,8 mm Hg (p<0,05) in the 1st subgroup; from 93,6±8,2 mm Hg to 81,3±6,48
mm Hg (p<0,05) in the 2d subgroup; from 94,8±8,3 mm Hg to 82,6±7,1 mm Hg (p<0,05) in the 3d subgroup accordingly. The treatment
with Noliprel/ Noliprel forte was equally efficacious in men and women of different age groups, in hypertensive pts both normal
and increased body mass as well as in pts with obesity of Grade 1. 96% of pts noticed excellent and very good tolerability of
Noliprel/ Noliprel forte treatment. After completing the study the medication was recommended for further treatment for 96% of pts.
Conclusions. Noliprel/Noliprel forte treatment results in the achievement of goal BP levels in the majority of pts with inadequate
BP control in different clinical situations. There was noticed an equal antihypertensive effects in young and old pts, in men and
women, in pts with normal and increased body mass as well as in pts with Grade 1 obesity. Noliprel/Noliprel forte treatment is characterized
by excellent tolerability.
About the Authors
Т. МартынюкRussian Federation
И. Колос
Russian Federation
И. Чазова
Russian Federation
T. V. Martyniuk
Russian Federation
I. P. Kolos
Russian Federation
I. E. Chazova
Russian Federation
References
1. Диагностика и лечению артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
2. Чазова И.Е. Комбинированная терапия артериальной гипертензии. Consilium Medicum. Прил. Артериальная Гипертензия. 2001: 22-26.
3. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М., 2007.
4. Bangalore S, Kamalakkannan G, Panjrath G, Messerli FH. Fixed-dose combination improves medication compliance: a meta-analysis. J Clin Hypertens 2006; 8(suppl. A).
5. Галеева З.М., Галявич А.С. Влияние фиксированной низкодозовой комбинации гипотензивных препаратов на клинико-биохимические характеристики больных артериальной гипертензией. Артериальная Гипертензия 2003; 9(6): 221-24.
6. Чукаева И.И., Шургая М.И. Особенности терапии артериальной гипертонии у женщин в климактерическом периоде. Болезни сердца и сосудов: актуальные и спорные вопросы. 2006; 2: 29-32.
Review
For citations:
, , , Martyniuk T.V., Kolos I.P., Chazova I.E. Final results of STRATEGYA Study (Russian Comparative Programme on a fixed, low-dose perindopril/indapamide combination efficacy in hypertensive patients with inadequate blood pressure control): use of a fixed, low- dose perindopril/indapamide combination in hypertensive patients in real clinical practice. Systemic Hypertension. 2009;(1):42-49.
Email this article 